Mankind Pharma IPO
Mankind Pharma IPO
Company
Mankind Pharma Ltd produces and sells consumer healthcare items in addition to pharmaceutical formulations for a range of acute and chronic therapeutic conditions.
The company’s primary market of concentration is the domestic market, which accounted for 97.6% of all operating revenue in the fiscal year 2022.
In India, it is the fourth-largest pharmaceutical firm by domestic sales.
Mankind Pharma runs 25 production plants all throughout India and has a national marketing presence. Also, it has one of the biggest medical representative distribution networks in the Indian pharmaceutical industry.
The complete public offering of Mankind Pharma Ltd is an OFS ( Offer For Sale ) from current shareholders to sell equity shares worth up to Rs. 4,326 crores.
Mankind Pharma IPO
| IPO date | 25 Apr 2023 – 27 Apr 2023 |
| Listing date | 09 May 2023 |
| Price range | RS 1026 – 1080 |
| Minimum order quantity | 13 |
| (D)RHP | View |
IPO Schedule
| Issue Period | 25th April to 27th April 2023 |
| Deadline for accepting UPI mandate | Until 5 PM on the issue closing day |
| Finalization of Allotment | 3rd May 2023 |
| Initiation of Refunds | 4th May 2023 |
| Credit of Shares | 8th May 2023 |
| Date of Listing | 9th May 2023 |
| Mandate end date | 12th May 2023 |
| Anchor Investors Lock-In End Date | 27th May 2023 |
Financial Information
| Financial Year | Total Assets (₹ crores) | Total Revenue (₹ crores) | Profit After Tax (₹ crores) | EBITDA (₹ crores) | ROCE |
| March 31, 2020 | 5,073.29 | 5,865.23 | 1,056.15 | 1448.35 | 35.86% |
| March 31, 2021 | 6,372.63 | 6,214.43 | 1,293.03 | 1659.78 | 30.41% |
| March 31, 2022 | 9,147.74 | 7,781.56 | 1,452.96 | 2003.80 | 25.50% |
Mankind Pharma IPO Allotment Link
You can check the allotment status for the Mankind Pharma Limited IPO on the website of the Registrar and Transfer agent.
Alternatively, you can also check the allotment status of Mankind Pharma Ltd on the NSE website.
If you like this blog please share and comment thanks.
This blog contains no recommendations. Please consult a financial advisor. This content is published for educational purposes.